Katrina A. Reardon

Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis

D. Papanicolaou, V. S. Williams, L. Tankó, 2020, Neurology.

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial

D. Papanicolaou, V. S. Williams, P. Bergh, 2019, The Lancet Neurology.

Study of levodopa response in Parkinson's disease: Observations on rates of motor progression

Velandai Srikanth, Catherine Ding, P. Kempster, 2016, Movement disorders : official journal of the Movement Disorder Society.

11C-PiB PET studies in typical sporadic Creutzfeldt–Jakob disease

C. Rowe, C. Masters, V. Villemagne, 2009, Journal of Neurology, Neurosurgery & Psychiatry.

Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease

P. Kempster, C. McColl, K. A. Reardon, 2002, Movement disorders : official journal of the Movement Disorder Society.

Inferring the long duration response to levodopa in Parkinson's disease.

P. Kempster, C. McColl, K. A. Reardon, 2019, Parkinsonism & related disorders.

The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease.

M. Horne, K. A. Reardon, F. Mendelsohn, 2000, Australian and New Zealand journal of medicine.

How long should a routine EEG be?

Lindsay J. Smith, I. Scheffer, D. Jolley, 1999, Journal of Clinical Neuroscience.

Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-Term Extension of RESILIENT.

D. Papanicolaou, V. S. Williams, L. Tankó, 2021, Neurology.

Evolution of motor fluctuations in Parkinson's disease: A longitudinal study over 6 years

P. Kempster, M. Shiff, Katrina A. Reardon, 1999, Movement disorders : official journal of the Movement Disorder Society.